There are several versions of Giritinib (Segatan) and explanations of differences at home and abroad.

Gilteritinib is a targeted drug for FLT3-mutated acute myeloid leukemia (AML). It is currently one of the important treatment options widely used worldwide for patients with refractory and relapsed AML. The drug was developed by Japan's Astellas Pharmaceutical Company and was first approved by the US FDA in 2018. Giritinib blocks the proliferation signaling pathways of tumor cells by inhibiting the activity of two receptor tyrosine kinases, FLT3 and AXL, helping patients prolong the remission period and improve survival rates.

At present, giritinib has been approved for marketing in mainland China, but it has not yet been included in the national medical insurance directory. Therefore, the price is still relatively high, and hospitals in some areas may not yet have full supply. If patients want to purchase through regular domestic channels, they usually need to go to a large tertiary hospital or apply for purchase through specially approved channels for imported drugs. In contrast, some patients will also choose overseas drug purchasing channels, especially looking for a more cost-effective version due to the large price difference.

In the international market, giritinib is mainly divided into two categories: original drugs and generic drugs. The original drug is produced by Astellas Pharmaceuticals. Common versions include the European version and the Hong Kong version. The Hong Kong version is priced higher, with a box of 30 tablets costing around 100,000 yuan. The price of the European version is slightly lower, but it still falls into the category of high-priced targeted drugs. The advantages of original drugs include stable quality, reliable data, and wide range of approvals, but their high cost has become a financial burden for many patients during their treatment.
In contrast, overseas generic drugs such as the Lao version of giritinib have greatly lowered the price threshold. Drugs of the same specifications produced by Lao pharmaceutical factories are priced between RMB 1,000 and RMB 2,000. The ingredients are basically the same as the original drugs and the efficacy is similar. This allows some patients with limited financial resources to adhere to treatment for a longer period of time. Generally speaking, although there are differences in price and packaging between different versions, the drug ingredients and clinical effects are basically the same. Patients should choose regular channels to purchase drugs under the guidance of a doctor to ensure safety and efficacy.
Reference: https://www.drugs.com/